References
- Rudd RA, Seth P, David F, et al. Increases in drug and opioid-involved overdose deaths – United States, 2010-2015. MMWR Morb Mortal Wkly Rep. 2016;65:1445–1452.
- Gowing L, Ali R, White JM, et al. Buprenorphine for managing opioid withdrawal. Cochrane Database Syst Rev. 2017;2:CD002025.
- Nielsen S, Larance B, Degenhardt L, et al. Opioid agonist treatment for pharmaceutical opioid dependent people. Cochrane Database Syst Rev. 2016;5:CD011117.
- Mattick RP, Breen C, Kimber J, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2:CD002207.
- Amato L, Davoli M, Minozzi S, et al. Methadone at tapered doses for the management of opioid withdrawal. Cochrane Database Syst Rev. 2013;2:CD003409.
- D’Onofrio G, O’Connor PG, Pantalon MV, et al. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA. 2015;313:1636–1644.
- Busch SH, Fiellin DA, Chawarski MC, et al. Cost-effectiveness of emergency department-initiated treatment for opioid dependence. Addiction. 2017;112:2002–2010.
- Berg ML, Idrees U, Ding R, et al. Evaluation of the use of buprenorphine for opioid withdrawal in an emergency department. Drug Alcohol Depend. 2007;86:239–244.
- Su MK, Lopez JH, Crossa A, et al. Low dose intramuscular methadone for acute mild to moderate opioid withdrawal syndrome. Am J Emerg Med. 2018;11:1951-1956. doi:10.1016/j.ajem.2018.02.019.
- Title 21 Code of Federal Regulations PART 1306. Diversion Control Division n.d. https://www.deadiversion.usdoj.gov/21cfr/cfr/1306/1306_07.htm (accessed May 2018).
- Emergency Narcotic Addiction Treatment. US Department of Justice Diversion Control Divison n.d. https://www.deadiversion.usdoj.gov/pubs/advisories/emerg_treat.htm (accessed May 2018).
- Bruneau J, Ahamad K, Goyer MÈ, et al. Management of opioid use disorders: a national clinical practice guideline. CMAJ. 2018;190:E247–E257.
- Gowing L, Farrell M, Ali R, et al. Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev. 2016;5:CD002024.
- Martel ML, Klein LR, Rivard RL, et al. A large retrospective cohort of patients receiving intravenous olanzapine in the emergency department. Acad Emerg Med. 2016;23:29–35.
- Cole JB, Moore JC, Dolan BJ, et al. A prospective observational study of patients receiving intravenous and intramuscular olanzapine in the emergency department. Ann Emerg Med..2017;69:327.e2–336.e2.
- Navari RM, Qin R, Ruddy KJ, et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med. 2016;375:134–142.
- Hill CH, Miner JR, Martel ML. Olanzapine versus droperidol for the treatment of primary headache in the emergency department. Acad Emerg Med. 2008;15:806–811.
- Yildiz A, Sachs GS, Turgay A. Pharmacological management of agitation in emergency settings. Emerg Med J. 2003;20:339–346.
- Richards JR, Richards IN, Ozery G, et al. Droperidol analgesia for opioid-tolerant patients. J Emerg Med. 2011;41:389–396.
- Chase PB, Biros MH. A retrospective review of the use and safety of droperidol in a large, high-risk, inner-city emergency department patient population. Acad Emerg Med. 2002;9:1402–1410.
- Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs. 2003;35:253–259.
- Tompkins DA, Bigelow GE, Harrison JA, et al. Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument. Drug Alcohol Depend. 2009;105:154–159.
- Chan EW, Taylor DM, Knott JC, et al. Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double-blind, placebo-controlled clinical trial. Ann Emerg Med. 2013;61:72–81.
- Taylor DM, Yap CYL, Knott JC, et al. Midazolam-droperidol, droperidol, or olanzapine for acute agitation: a randomized clinical trial. Ann Emerg Med. 2017;69:318.e1–326.e1.
- Schreiber S, Getslev V, Backer MM, et al. The atypical neuroleptics clozapine and olanzapine differ regarding their antinociceptive mechanisms and potency. Pharmacol Biochem Behav. 1999;64:75–80.
- Torigoe K, Nakahara K, Rahmadi M, et al. Usefulness of olanzapine as an adjunct to opioid treatment and for the treatment of neuropathic pain. Anesthesiology. 2012;116:159–169.
- Go SI, Song HN, Lee SJ, et al. Craving behavior from opioid addiction controlled with olanzapine in an advanced cancer patient: a case report. J Palliat Med. 2018;21:1367–1370.
- Schwartz NA, Turturro MA, Istvan DJ, et al. Patients’ perceptions of route of nonsteroidal anti-inflammatory drug administration and its effect on analgesia . Acad Emerg Med. 2000;7:857–861.
- Peerdeman KJ, Tekampe J, van Laarhoven AIM, et al. Expectations about the effectiveness of pain- and itch-relieving medication administered via different routes. Eur J Pain. 2018;22:774–783.
- Catapres (clonidine hydrochloride) Label - FDA n.d. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/017407s034lbl.pdf (accessed June 2018).
- Cole JB, Klein LR, Martel ML. Parenteral antipsychotic choice and its association with ED length of stay for acute agitation secondary to alcohol intoxication. Acad Emerg Med. 2018; doi:10.1111/acem.13486. [Epub ahead of print]